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Abstract We show here for the ¢rst time that sphingosine-1-
phosphate (Sph-1-P) stimulates cortisol secretion in zona fasci-
culata cells of bovine adrenal glands. This e¡ect was dependent
upon protein kinase C (PKC) and extracellular Ca2+, and was
inhibited by pertussis toxin. Sph-1-P activated phospholipase D
(PLD) through a pertussis toxin-sensitive mechanism, also in-
volving extracellular Ca2+ and PKC. Primary alcohols, which
attenuate formation of phosphatidic acid (the product of PLD),
and cell-permeable ceramides, which inhibit PLD, blocked Sph-
1-P-induced cortisol secretion. In conclusion, Sph-1-P stimu-
lates cortisol secretion through a mechanism involving Gi/o pro-
tein-coupled receptors, extracellular Ca2+, PKC and PLD.
/ 2003 Federation of European Biochemical Societies. Pub-
lished by Elsevier Science B.V. All rights reserved.
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1. Introduction
Sphingosine-1-phosphate (Sph-1-P) has been described as a
potent bioactive lysophospholipid that is implicated in the
regulation of many critical cell functions [1,2]. It is formed
by ATP-dependent phosphorylation of sphingosine by sphin-
gosine kinase, and can be metabolized by pyridoxal phos-
phate-dependent lyase and phosphatase activities [1,3]. Acti-
vation of sphingosine kinase and enhanced formation of Sph-
1-P was shown to be induced by platelet-derived growth fac-
tor, but not epidermal growth factor, leading to mitogen-ac-
tivated protein kinase activation and the regulation of cell
proliferation [4]. In addition, Sph-1-P has been shown to act
intracellularly as a second messenger to inhibit apoptosis and
promote cell survival [1,2]. Another mechanism whereby Sph-
1-P can elicit biological responses is its interaction with spe-
ci¢c G protein-coupled receptors of the EDG (endothelin dif-
ferentiation gene) family [1,5]. Sph-1-P is stored at high con-
centrations in human platelets, or in mast cells, and can be
released into the blood stream upon activation by physiolog-
ical stimuli [6]. Stimulation of these receptors has been asso-
ciated with the regulation of cell di¡erentiation, smooth
muscle contraction, cell migration, inhibition of tumor cell
invasion, and angiogenesis [5,7]. The biological e¡ects elicited
by Sph-1-P involve activation of diverse signaling pathways
including stimulation of phosphatidylinositol-dependent phos-
pholipase C (PI-PLC), mitogen-activated protein kinase
ERK1/2, phosphatidylinositol 3-kinase, phospholipase D
(PLD), or transcription factors such as AP-1 [1,5,8]. Further-
more, Sph-1-P can mobilize inositol trisphosphate (IP3)-sensi-
tive and -insensitive intracellular Ca2þ stores [9,10].
In the present study, we demonstrate for the ¢rst time that
Sph-1-P stimulates the secretion of cortisol in zona fasciculata
(ZF) cells of bovine adrenal glands and provide evidence on
the mechanisms whereby Sph-1-P exerts this action. The data
presented demonstrate a novel role of Sph-1-P in the regula-
tion of steroid secretion.
2. Materials and methods
2.1. Materials
Bovine serum albumin (BSA; fraction V), and collagenase P and A
were from Boehringer Mannheim (Mannheim, Germany). Angioten-
sin II, cortisol, Dulbecco’s modi¢ed Eagle’s medium (DMEM),
EGTA, HEPES, pertussis toxin (PTX), lysophosphatidate (LPA),
and sphingomyelinase (from Bacillus cereus or Streptomyces sp.)
were from Sigma (St. Louis, MO, USA). [3H]Myristate, [3H]cortisol
and myo-[1-2-3H]inositol were supplied by American Radiolabeled
Chemicals (St. Louis, MO, USA). Sphingosine, Sph-1-P, N-acetyl-
sphingosine (C2-ceramide), dihydro-C2-ceramide, N-octanoyl-Sph-1-
P, and phosphatidylethanol standard were from Avanti Polar Lipids
(Alabaster, AL, USA). Fura 2-AM was from Molecular Probes (Eu-
gene, OR, USA). 4L-Phorbol 12-myristate 13-acetate (PMA) was
from Alexis (La«ufel¢ngen, Switzerland).
2.2. Cell preparation and culture
Cells were isolated and puri¢ed from the ZF of adrenal glands
obtained from 1 year old steers, as described [11]. Cells were seeded
in 35 mm culture dishes (8U105 cells per dish), or in 12 well plates
(3.5U105 cells per well). After 24 h, the medium was replaced by fresh
DMEM supplemented with 10% fetal bovine serum (FBS) and cells
incubated further for 2 days in a gassed, humidi¢ed incubator (5%
CO2 at 37‡C) before use in experiments. This time was chosen because
steroid output from these cells increases to a maximum by 48^72 h
[11].
2.3. Determination of cortisol secretion
Cortisol output was measured by radioimmunoassay, as described
[12]. Cells were washed twice in DMEM supplemented with 0.2%
BSA, and incubated for 2.5 h in this same medium. No intermediate
washes were carried out during the procedure to prevent the burst of
sphingolipids and diacylglycerol that occurs rapidly after changing the
medium [13,14]. Agonists were then added and cells incubated further
for 2 h. The medium was then recovered for determination of cortisol
content.
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2.4. Assay of PLD
PLD was determined by measuring the production of
[3H]phosphatidylethanol, as described [15]. Brie£y, cells were incuba-
ted for 3 h with 1 WCi [3H]myristate/ml to label cell phosphatidylcho-
line, washed twice and then incubated for 2.5 h with no intermediate
washes. Ethanol, at a ¢nal concentration of 1%, was added 5 min
prior to addition of agonists. Lipids were extracted as described [16]
and separated by thin layer chromatography. The plates were devel-
oped with chloroform/methanol/acetic acid (9:1:1, v/v), and the posi-
tion of lipids was identi¢ed after staining with I2 vapor by comparison
with authentic standards. Radioactive lipids were quantitated by liq-
uid scintillation counting.
2.5. Assay of PI-PLC
PI-PLC was determined as described [17]. Brie£y, ZF cells were
incubated for 24 h at 37‡C in DMEM supplemented with 10% FBS
containing 1 WCi/ml of myo-[1-2-3H]inositol to label cell phosphoino-
sitides. Cells were then washed twice and incubated in BSA-free me-
dium with 10 mM LiCl for 2.5 h. Agonists were added as required,
and reactions stopped with 0.5 ml of 5% HClO4 and 100 Wl BSA (20
mg/ml). The [3H]inositol phosphates were separated from [3H]inositol
by retention on columns of ion-exchange resin (Dowex AG1-X8, 100^
200 mesh) as described [18].
2.6. cAMP determination
Cells were preincubated for 20 min with 1 mM isobutylmethylxan-
thine, prior to agonist addition, and then treated as described [19].
cAMP levels were determined using an enzyme immunoassay kit from
Amersham.
2.7. Statistical analysis
Unless stated otherwise, results are expressed as meansTS.E.M. of
the indicated number of experiments performed in triplicate. Statisti-
cal signi¢cance of the di¡erence between means of control and exper-
imental conditions was assessed with Student’s paired t-test. Values of
P9 0.05 were considered signi¢cant.
3. Results and discussion
Sph-1-P stimulated the secretion of cortisol in ZF cells of
bovine adrenal glands. This e¡ect was speci¢c for Sph-1-P as
other bioactive sphingolipids such as sphingosine, N-octanoyl-
Sph-1-P, or the structurally related lysoglycerophospholipid
LPA were without e¡ect (Fig. 1). The cells were also stimu-
lated with concentrations of these compounds of up to 50 WM,
or with the cell-permeable C2-ceramide (at 10 or 50 WM), but
no elevation in cortisol levels was detected.
It is well established that adrenocortical ZF cells secrete
high amounts of cortisol in response to ACTH, or L1-adren-
ergic agonists, through stimulation of adenylyl cyclase [11,20].
Interestingly, Sph-1-P stimulated cortisol secretion to a similar
extent to that of adrenaline, but in contrast to this hormone,
it did not stimulate cAMP formation. In addition, Sph-1-P
failed to alter ACTH-stimulated cAMP generation (data not
shown). Although Sph-1-P is rapidly taken up by cells and
acts intracellularly, some of its biological e¡ects are caused by
binding to speci¢c receptors that are coupled to PTX-sensitive
Gi/o proteins [1,21]. We found that the stimulation of cortisol
secretion by Sph-1-P was potently decreased by PTX, suggest-
ing that this is a process mediated by Gi/o-coupled receptors
(Fig. 2). It was also reported that cortisol secretion can be
regulated by protein kinase C (PKC) and Ca2þ independently
of cAMP [22]. Therefore, we examined the implication of
these factors in the stimulation of cortisol secretion by Sph-
1-P. The involvement of PKC was studied by preincubating
the cells with PMA (2 WM) for 48 h, as this condition causes
downregulation of PKC in bovine adrenal glomerulosa cells
[23]. Under these conditions, the cells lost their sensitivity to
stimulation of cortisol secretion by PMA [cortisol output was
decreased from 3.15T 0.60 fold to 1.12 T 0.13 (meanTS.E.M.
of ¢ve independent experiments, P6 0.05)], and the e¡ect of
Sph-1-P was substantially decreased (Fig. 2). Similar results
were obtained by preincubating the cells for 30 min with the
selective PKC inhibitor Ro-32-0432 (1 WM) prior to Sph-1-P
addition (not shown). Therefore, these results suggest that
PKC is involved in Sph-1-P-stimulated cortisol secretion.
This e¡ect was almost completely abolished by combined pre-
incubation with PMA and PTX (Fig. 2). We then evaluated
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Fig. 1. Stimulation of cortisol secretion by di¡erent lipid agonists.
Cells were stimulated for 2 h with increasing concentrations of Sph-
1-P (solid circles), sphingosine (empty circles), N-octanoyl-Sph-1-P
(squares), or LPA (triangles). For experimental details see Section 2.
Results are expressed as fold stimulation relative to incubations
with vehicle, and show the meanTS.E.M. of four independent ex-
periments, except for the value at 5 WM Sph-1-P, which is the
meanTS.E.M. of 36 experiments. Basal value of cortisol secretion
was 7.6 T 1.0 ng/mg protein (meanTS.E.M., n=48).
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Fig. 2. E¡ect of PTX and PMA on Sph-1-P-stimulated cortisol se-
cretion. Cells were treated as in Fig. 1. They were preincubated
with vehicle (empty bars), 2 WM PMA for 48 h (hatched bars),
1 Wg/ml PTX for 16 h (dotted bars), or with PTX and PMA (solid
bars), as indicated. Sph-1-P (5 WM) was then added and the incuba-
tions continued for a further 2 h. CTRL indicates incubations in
the absence of Sph-1-P (controls). Results are calculated as in Fig. 1,
and they are expressed as meanTS.E.M. of three independent ex-
periments.
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whether Ca2þ was necessary for stimulation of cortisol secre-
tion by Sph-1-P. Addition of EGTA inhibited this e¡ect sig-
ni¢cantly, suggesting that extracellular Ca2þ is essential in this
process (Fig. 3). Although Sph-1-P can also increase cytosolic
Ca2þ from internal stores by both IP3-dependent and -inde-
pendent mechanisms [9,10], it did not stimulate PI-PLC, and
the secretion of cortisol was not inhibited further by combined
pretreatment of cells with EGTA and the intracellular Ca2þ
chelators Fura 2-AM, or BAPTA-AM (Fig. 3). The e⁄ciency
of Fura 2-AM to chelate Ca2þ was tested further by stimulat-
ing the cells with the Ca2þ ionophore A23187 in the absence
of EGTA. A23187 (1 WM) stimulated cortisol secretion by
2.6T 0.3 fold (meanTS.E.M. of three independent experi-
ments) and this was blocked by 10 WM Fura 2-AM. These
data suggest that extracellular Ca2þ, but not intracellular mo-
bilization of this cation, is relevant for the stimulation of
cortisol secretion by Sph-1-P.
Another signaling pathway that can be activated by Sph-1-
P is the PLD pathway [8,24]. Fig. 4 shows that Sph-1-P acti-
vates PLD in ZF cells. Like stimulation of cortisol secretion,
PLD activation was blocked by (a) chelating extracellular
Ca2þ with EGTA, (b) downregulation of PKC, and (c) treat-
ment with PTX (Fig. 5A^C, respectively). These observations
are in agreement with previous work in macrophages [25,26]
and Beas-2B cells [27]. Therefore, we hypothesized that PLD
might be involved in Sph-1-P-stimulated cortisol secretion. To
assess this possibility, cortisol output was examined in the
presence of primary alcohols, which reduce the levels of phos-
phatidate (PA), the product of PLD, by forming phosphati-
dylalcohols through transphosphatidylation, a reaction cata-
lyzed uniquely by PLD. ‘Alcohol trap’ experiments have been
utilized to establish the role of PLD in various physiological
responses. We found that the optimal concentrations of pri-
mary alcohols used for PLD determinations, 1% ethanol or
0.3% 1-butanol [5,15,28,29], decreased Sph-1-P-stimulated
cortisol secretion by 41T 2% and 33T 6%, respectively
(meanTS.E.M. of three independent experiments, P6 0.05).
However, alcohols might have e¡ects on cortisol secretion
independently of PLD. Therefore, in some experiments, the
cells were stimulated in the presence of 2-butanol, as second-
ary alcohols are not substrates for PLD [5,30]. Contrary to
1-butanol, concentrations of up to 0.3% of 2-butanol did not
a¡ect the stimulation of cortisol secretion by Sph-1-P, suggest-
ing that the inhibitory e¡ect of primary alcohols was caused
by decreasing the levels of PLD-derived PA. To further rule
out a possible non-speci¢c e¡ect of primary alcohols on cor-
tisol secretion, the cells were stimulated with 22-R-hydroxy-
cholesterol, a hydrophilic cholesterol analogue that can by-
pass the usual signaling pathways necessary for steroid
secretion [31]. We found that 22-R-hydroxycholesterol
(1 WM) stimulated the secretion of cortisol by about 9.6 T
1.1 fold (meanTS.E.M., n=3), and this was not signi¢cantly
altered by 1% ethanol or 0.3% 1-butanol. The implication of
PLD in Sph-1-P-induced cortisol secretion was further eval-
uated by stimulating the cells in the presence of ceramides,
which are potent inhibitors of PLD [32]. As expected, C2-cer-
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Fig. 3. E¡ect of EGTA, Fura 2-AM, and BAPTA-AM on Sph-1-P-
induced cortisol secretion. Cells were preincubated for 30 min with
vehicle (empty bars), 5 mM EGTA (hatched bars), 10 WM Fura
2-AM (dotted bars), 5 WM BAPTA-AM (striped bars), EGTA and
Fura 2-AM (solid bars), or EGTA and BAPTA-AM (double-
hatched bars), as indicated. Sph-1-P (5 WM) was then added and in-
cubations continued for a further 2 h. CTRL indicates incubations
in the absence of Sph-1-P (controls). Results are calculated as in
Fig. 1, and they are expressed as meanTS.E.M. of three indepen-
dent experiments.
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Fig. 4. Sph-1-P stimulates PLD in ZF cells. Cells were treated and
labeled as indicated in Section 2. They were stimulated with increas-
ing concentrations of Sph-1-P for 30 min (A), or with 5 WM Sph-1-
P for various times (B). Results were calculated as a percentage of
the radioactivity present in [3H]phosphatidylethanol compared to
that in total lipids, and expressed as the fold stimulation relative to
incubations with vehicle. Results are the meansTS.E.M. of three in-
dependent experiments.
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amide (10 WM) completely blocked the stimulation of PLD by
Sph-1-P, whereas the inactive analogue dihydro-C2-ceramide
had no e¡ect (Fig. 6A). Likewise, the stimulation of cortisol
secretion by Sph-1-P was completely abolished by C2-ceram-
ide (100 WM), but not by dihydro-C2-ceramide (Fig. 6B). The
reason why a 100 WM concentration of ceramide was used in
these experiments is because cortisol secretion was determined
in the presence of a relatively high concentration of BSA
(0.2%), which binds ceramide very tightly and makes it un-
available to cells [33]. Taken together, these results suggest
that the stimulation of cortisol secretion by Sph-1-P involves
PLD activation.
In conclusion, here we demonstrate that Sph-1-P is a potent
stimulator of cortisol secretion in bovine ZF cells. Our results
suggest that extracellular Ca2þ, Gi/o proteins, PKC, and PLD
are all important components in the cascade of events leading
to the stimulation of cortisol secretion by Sph-1-P.
Acknowledgements: This study was supported by Grants 1UPV/EHU
00042.310-EA-8014/2000 from the Universidad del Pa|¤s Vasco, and
PI99/8 from the Departamento de Educacio¤n, Universidades e Inves-
tigacio¤n del Gobierno Vasco (Basque Country).
A
3
2
1
0
R
e
la
ti
ve
 P
L
D
 a
c
ti
vi
ty
CTRL Sph 1-P
B
3
2
1
0
R
e
la
ti
ve
 P
L
D
 a
c
ti
vi
ty
CTRL Sph 1-P
C
3
2
1
0
R
e
la
ti
ve
 P
L
D
 a
c
ti
vi
ty
CTRL Sph 1-P
Fig. 5. E¡ects of EGTA, PMA and PTX on PLD activation by
Sph-1-P. Cells were treated and labeled as indicated in Section 2,
and they were preincubated with vehicle (empty bars) or with the
following additions (solid bars): 5 mM EGTA for 30 min (A), 2 WM
PMA for 48 h (B), or 1 Wg/ml PTX for16 h (C). Sph-1-P (5 WM)
was then added and incubations continued further for 30 min, as
indicated. CTRL indicates incubations in the absence of Sph-1-P
(controls). In each case, results are calculated as in Fig. 4, and
show the meansTS.E.M. of three independent experiments.
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Fig. 6. Inhibition of Sph-1-P-stimulated PLD and cortisol secretion
by C2-ceramide. Cells were treated and labeled as described in Sec-
tion 2. A: Cells were preincubated with vehicle (empty bars), 10
WM C2-ceramide (solid bars), or 10 WM dihydro-C2-ceramide
(hatched bars) for 2 h in BSA-free DMEM. Sph-1-P (5 WM) was
then added and incubations continued further for 30 min. B: Cells
were preincubated with vehicle (empty bars), 100 WM C2-ceramide
(solid bars), or 100 WM dihydro-C2-ceramide (hatched bars) for 2 h
in DMEM supplemented with 0.2% BSA. In each case, Sph-1-P
(5 WM) was then added and incubations continued for a further 2 h.
CTRL indicates incubations in the absence of Sph-1-P (controls).
Values in A are calculated as in Fig. 4, and values in B are calcu-
lated as in Fig. 1. Results are expressed as the fold stimulation rela-
tive to incubations with vehicle in each case, and they show the
meansTS.E.M. of three or four independent experiments.
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